Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774527 | 1.00 | HRH4 (0.58) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL1774848 | 0.88 | HRH3 (0.45) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL1774211 | 0.84 | MAP4K4 (0.45) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL1775967 | 0.84 | MAP4K4 (0.45) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL25142073 | 0.80 | HRH4 (0.43) | HRH4HRH3MAP4K4JAK3EGLN2 | |
| SCHEMBL4039899 | 0.79 | HRH4 (0.68) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL17748984 | 0.78 | OPRD1 (0.39) | HRH4HRH3MAP4K4 | |
| SCHEMBL18601608 | 0.77 | HRH4 (0.76) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL1775396 | 0.77 | HRH4 (0.76) | HRH4HRH3MAP4K4JAK2JAK3 | |
| SCHEMBL1777786 | 0.75 | HRH4 (0.73) | HRH4HRH3MAP4K4JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885HRH3 187/4885MAP4K4 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.